3 US Stocks Estimated To Be Undervalued By Up To 42%

In This Article:

As the U.S. stock market begins to rebound from a sluggish start in 2025, with major indices like the S&P 500 and Nasdaq snapping multi-day losing streaks, investors are keenly observing opportunities that may arise from recent volatility. In this context, identifying undervalued stocks becomes crucial as they can offer potential value by trading below their intrinsic worth amidst fluctuating market conditions.

Top 10 Undervalued Stocks Based On Cash Flows In The United States

Name

Current Price

Fair Value (Est)

Discount (Est)

Clear Secure (NYSE:YOU)

$27.27

$53.03

48.6%

Dime Community Bancshares (NasdaqGS:DCOM)

$30.89

$61.61

49.9%

German American Bancorp (NasdaqGS:GABC)

$39.06

$77.34

49.5%

Camden National (NasdaqGS:CAC)

$42.08

$83.90

49.8%

Ally Financial (NYSE:ALLY)

$35.85

$71.62

49.9%

Kanzhun (NasdaqGS:BZ)

$13.95

$27.36

49%

Constellium (NYSE:CSTM)

$10.52

$20.92

49.7%

Mr. Cooper Group (NasdaqCM:COOP)

$95.39

$187.71

49.2%

Progress Software (NasdaqGS:PRGS)

$65.26

$128.87

49.4%

South Atlantic Bancshares (OTCPK:SABK)

$15.59

$30.75

49.3%

Click here to see the full list of 177 stocks from our Undervalued US Stocks Based On Cash Flows screener.

Underneath we present a selection of stocks filtered out by our screen.

Micron Technology

Overview: Micron Technology, Inc. is a company that designs, develops, manufactures, and sells memory and storage products globally with a market cap of approximately $100.13 billion.

Operations: Micron's revenue segments include the Compute and Networking Business Unit (CNBU) at $12.17 billion, Mobile Business Unit (MBU) at $6.59 billion, Storage Business Unit (SBU) at $5.67 billion, and Embedded Business Unit (EBU) at $4.63 billion.

Estimated Discount To Fair Value: 17.2%

Micron Technology, trading at US$89.87, is considered undervalued based on discounted cash flow analysis with an estimated fair value of US$108.59. Recent earnings showed a strong recovery with sales reaching US$8.71 billion and net income of US$1.87 billion for the first quarter of fiscal 2025, compared to losses in the previous year. The company expects continued earnings growth, supported by innovative product launches like the Micron 6550 ION NVMe SSD for data centers.

NasdaqGS:MU Discounted Cash Flow as at Jan 2025
NasdaqGS:MU Discounted Cash Flow as at Jan 2025

Vertex Pharmaceuticals

Overview: Vertex Pharmaceuticals Incorporated is a biotechnology company focused on developing and commercializing therapies for treating cystic fibrosis, with a market cap of approximately $104.84 billion.